Phenytoin sodium capsules are used in the treatment of epilepsy to prevent and control seizures, and are an important drug for an estimated 48,000 patients in the UK. As a result, Britain’s National Health Service annual spending for the drug rose from roughly $2.5 million in 2012 to approximately $63 million the following year. “Businesses are generally free to set prices as they see fit but those holding a dominant position should not abuse this situation and set prices that are excessive and unfair,” Philip Marsden, chairman of the CMA’s case decision group for the investigation, said in a statement. Additionally, a £5.2 million fine applies on the distributor Flynn Pharma. The medication was “a loss making product” for the company, Pfizer said in a formal statement. The company denied the allegation and said it would appeal.